Search results
Showing 91 to 105 of 870 results for score
Delgocitinib for treating moderate to severe chronic hand eczema (TA1107)
Evidence-based recommendations on delgocitinib (Anzupgo) for treating moderate to severe chronic hand eczema in adults when topical corticosteroids have not worked or are not suitable.
Xeomin (botulinum neurotoxin type A) for treating chronic sialorrhoea (TA605)
Evidence-based recommendations on Xeomin (botulinum neurotoxin type A) for treating chronic sialorrhoea (excessive salivation and drooling) caused by neurological conditions in adults.
Total hip replacement and resurfacing arthroplasty for end-stage arthritis of the hip (TA304)
Evidence-based recommendations on artificial hips and hip resurfacing for treating end-stage arthritis of the hip in adults.
View recommendations for TA304Show all sections
Baricitinib for treating moderate to severe atopic dermatitis (TA681)
Evidence-based recommendations on baricitinib for treating moderate to severe atopic dermatitis in adults.
This quality standard covers assessing, diagnosing and managing rheumatoid arthritis in over 16s. It describes high-quality care in priority areas for improvement.
Denosumab for the prevention of osteoporotic fractures in postmenopausal women (TA204)
Evidence-based recommendations on denosumab (Prolia) for preventing osteoporotic fragility fractures in postmenopausal women.
Evidence-based recommendations on adalimumab, etanercept, infliximab and abatacept for adults with moderate rheumatoid arthritis who have tried conventional DMARDs but they have not worked.
Dupilumab for treating moderate to severe atopic dermatitis (TA534)
Evidence-based recommendations on dupilumab (Dupixent) for treating moderate to severe atopic dermatitis in adults.
Subarachnoid haemorrhage caused by a ruptured aneurysm: diagnosis and management (NG228)
This guideline covers diagnosing and treating an aneurysmal (caused by a ruptured aneurysm) subarachnoid haemorrhage and its complications. It provides recommendations to improve diagnosis and ensure that the most effective treatments are offered. It includes guidance on follow-up care and information for people (aged 16 and over) who have had an aneurysmal subarachnoid haemorrhage, their families and carers.
Summary of the evidence on lurasidone (Latuda) for schizophrenia in adults aged 18 and over to inform local NHS planning and decision-making
Stroke and transient ischaemic attack in over 16s: diagnosis and initial management (NG128)
This guideline covers interventions in the acute stage of a stroke or transient ischaemic attack (TIA). It offers the best clinical advice on the diagnosis and acute management of stroke and TIA in the 48 hours after onset of symptoms.
Summary of the evidence on oxybutynin for treating hyperhidrosis (excessive sweating) to inform local NHS planning and decision-making
Esketamine nasal spray for treatment-resistant depression (TA854)
Evidence-based recommendations on esketamine (Spravato) for treatment-resistant depression in adults.
Cardiovascular disease. Patient decision aid on should I take a statin?
you also need to think about your age and your health overall. My QRISK score is: Date: 2 What can I do to reduce my risk? There are...
This quality standard covers identifying, assessing and managing chronic liver disease in children, young people and adults, and cirrhosis in young people and adults. It describes high-quality care in priority areas for improvement.
View quality statements for QS152Show all sections
Sections for QS152
- Quality statements
- Quality statement 1: Advice on physical activity, diet and alcohol
- Quality statement 2 (developmental): Testing for advanced liver fibrosis
- Quality statement 3 (developmental): Non-invasive testing for cirrhosis
- Quality statement 4: Surveillance for hepatocellular carcinoma
- Quality statement 5: Prophylactic intravenous antibiotics for upper gastrointestinal bleeding
- Update information
- About this quality standard